[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

44

1 and the low protein as well. The next slide, please
2 -- shows that in a different patient the responses
3 were very large indeed.
4 You saw the development of responses not
5 only to the immunogens and the other baculovirus and
6 the low protein, but also quite vigorous responses
7 with stimulation indices of 100 at times to a
8 recombinant envelope protein prepared in a different
9 system and made from a different genomic sequence.
10 Also quite conspicuous in this patient
11 were the development of increased immune responses to
12 P-24 antigen, an antigen which is not in the
13 immunogen. This is not in the vaccine. These
14 individuals can have seen P-24 only by virtue of their
15 own ihfection, and they respond after administration
16 of the envelope protein in a way that they did not
17 respond before administration of the envelope protein.
18 The next slide shows the aggregate data,
19 indicating that these responses were not observed in
20 the Hepatitis vaccine recipients, were observed at
21 each of the doses to roughly equivalent degrees in
22 recipients of gp-160. These values are not
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]